

## **OrganTech Completes Financing to Support Its Next Stage of Growth**

### **Accelerating Global Expansion Centered on Bio-hybrid Tooth and the “Third Cell Type” for Hair Follicle Regeneration**

**Tokyo, Japan** — OrganTech, Inc. (Headquarters: Tokyo, Japan; CEO: Yoshio Shimo, hereinafter “OrganTech”), a biotechnology company committed to the practical application of organ regenerative technologies, today announced the successful completion of a financing round to support its next stage of growth.

OrganTech is advancing research and development toward the practical application of its Bio-hybrid Tooth, which aims to regenerate periodontal ligament function, as well as its “Third Cell Type” (Hair Follicle Supportive Cell), a hair follicle-derived cell population. The Company also operates a research and development support business utilizing three-dimensional artificial skin technologies for healthcare and related industries.

Through this financing, OrganTech will further accelerate research and development activities in regenerative medicine, strengthen its business foundation, and expand its operations both in Japan and internationally.

#### **Key Areas of Investment**

- Advancement of research and clinical development of the Bio-hybrid Tooth
- Strengthening of regulatory and business development capabilities in Japan and overseas
- Establishment of manufacturing and scalable production technologies
- Promotion of partnerships to support future global expansion
- Acceleration of hair regeneration research and business development based on the “Third Cell Type”
- Expansion of regenerative medicine pipeline programs, including artificial skin technologies

#### **Advancing the Bio-hybrid Tooth Toward Practical Application**

The Bio-hybrid Tooth has attracted significant interest in Japan and internationally as a next-generation bio-implant aimed at becoming a third category of natural tooth replacement, distinct from conventional dental implants.

OrganTech is currently advancing initiatives toward practical application in Japan while also



pursuing regulatory and business development activities in preparation for future expansion into the United States.

In August 2025, OrganTech entered into a consulting agreement with QNova LifeSciences, a Maryland-based life sciences CRO and consulting organization operated by LifeSciences Regulatory Solutions, LLC. The two companies are working together to prepare for future regulatory submissions to the U.S. Food and Drug Administration (FDA) related to OrganTech's next-generation bio-implant technology.

A research group led by the Dental and Maxillofacial Implant Center of Minami Tohoku Medical Clinic initiated a specified clinical research study of the periodontal ligament-integrated implant on February 1, 2025. Four patients have received implantation procedures, and engraftment has been confirmed in all cases reported to date.

### **Government-Supported Innovation Initiative**

OrganTech's next-generation bio-implant project has been selected for the FY2025 **Tokyo Strategic Innovation Promotion Program**, administered by the Tokyo Metropolitan Small and Medium Enterprise Support Center. Through this program, the Company is eligible to receive support for up to three years.

### **Discovery of the "Third Cell Type" for Hair Follicle Regeneration**

In February 2026, OrganTech and the Organ Induction Research Team of the RIKEN Center for Biosystems Dynamics Research announced the discovery of **Hair Follicle Supportive Cells**, a newly identified cell population that supports the development, growth, and regeneration of hair follicles.

The research findings were published in *Biochemical and Biophysical Research Communications* and were featured by more than 1,000 domestic and international media outlets, including coverage distributed through the Associated Press.

OrganTech is also advancing commercialization activities based on this technology. The Company has granted Kojin Bio Co., Ltd. a manufacturing license for cell-derived components originating from Hair Follicle Supportive Cells and Dermal Papilla Cells.

### **Looking Ahead**

Under its mission of contributing to improved quality of life through regenerative medical technologies that harmonize with the human body, OrganTech is evolving from a research-driven organization into a business creation-oriented company.

By creating new markets while further deepening its existing businesses, OrganTech aims to

strengthen both its long-term growth and business stability.



#### ■ About OrganTech. Inc.

OrganTech is a regenerative medicine company founded on the organ germ method, a technology platform originally developed through pioneering research in epithelial-mesenchymal interaction-driven organogenesis. The company is advancing next-generation bioengineered organ technologies, including hair follicle regeneration, dental bio-hybrid implants, and three-dimensional artificial skin systems. OrganTech aims to establish scalable organ-level regenerative solutions addressing large unmet medical needs worldwide.

#### ■ Contact Information

OrganTech. Inc.

Email: [info@organ-tech.jp](mailto:info@organ-tech.jp)